Post-Transplant Cyclophosphamide in Patients Aged >/=70 Years Undergoing Haploidentical Transplant
Status:
Not yet recruiting
Trial end date:
2028-07-01
Target enrollment:
Participant gender:
Summary
The purpose of this phase 1 study is to determine the optimal dose of the immune suppressive
drug, cyclophosphamide, following standard allogeneic stem cell transplant in patients aged
>/= 70 years with hematologic malignancies.